Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
0 hedge funds and large institutions have $0 invested in Sucampo Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $21K → $0 (-$21K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$8K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$7K |
| 3 |
AIM
Advantage Investment Management
Cedar Rapids,
Iowa
|
-$6K |
SCMP Hedge Fund Activity: Q2 2018 in Review
0 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q2 2018, worth a combined $0 — down 100% from $21K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCMP and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Glenmede Trust, exiting entirely with an estimated $8K sold.
- 0 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q2 2018, down from 3 in Q1 2018.
- Funds reported $0 of Sucampo Pharmaceuticals, Inc. stock for Q2 2018, down 100% quarter-over-quarter.
- 0 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q2 2018 and 3 closed out, a net change of -3 holders.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q2 2018 was Glenmede Trust, an estimated $8K sold.
Based on aggregated 13F filings for Q2 2018.